Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Mylan, Fujifilm Kyowa Kirin Biologics Receive Marketing Authorization for Biosimilar to Humira

By Mylan N.V. | September 20, 2018

Mylan and Fujifilm Kyowa Kirin Biologics Co. today announced that the European Commission (EC) has granted marketing authorization for Hulio, a biosimilar to AbbVie’s Humira (adalimumab), for all indications.

The authorization follows the adoption of a positive opinion by the Committee for Medicinal Products for Human Use (CHMP), which concluded that the development program including analytical, functional, clinical and immunogenicity data demonstrated biosimilarity with the reference product, Humira.

The EC approval of Hulio applies to all 28 European Union (EU) member countries and European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. Mylan plans to launch Hulio across various markets in Europe on or after Oct. 16. Mylan and Fujifilm Kyowa Kirin Biologics partnered earlier this year. Fujifilm Kyowa Kirin Biologics has a nonexclusive royalty bearing license with AbbVie (Mylan has a sublicense) for the use and sale of Hulio in European countries.

Mylan President Rajiv Malik commented, “We’re very pleased with the decision of the European Commission to grant marketing authorization for Hulio. This is the fourth product that Mylan will be bringing to market in the area of complex generics and biosimilars, and we’re proud to be a leader in the market formation. We’ve made great progress with Fujifilm Kyowa Kirin Biologics and look forward to continuing this important collaboration.”

“We are delighted that Hulio has received approval from the European Commission,” said Dr. Yoshifumi Torii, Fujifilm Kyowa Kirin Biologics president and CEO. “The EC’s approval of Hulio marks a significant milestone. In cooperating with Mylan, we continue to commit all efforts to bring high quality and affordable biosimilars to patients throughout European countries.”

Mylan Europe President Jacek Glinka added, “Biosimilars represent a huge opportunity in Europe to drive better patient access through high quality, value medications that support healthcare systems across the region to deliver ongoing excellent care in the face of aging populations and increasingly stretched resources.”

Hulio is indicated for the same indications of Humira, including:

Adults

  • Rheumatoid arthritis
  • Ankylosing spondylitis
  • Axial spondyloarthritis without radiographic evidence of ankylosing spondylitis
  • Psoriatic arthritis
  • Psoriasis
  • Hidradenitis suppurativa
  • Crohn’s disease
  • Ulcerative colitis
  • Uveitis

Children

  • Polyarticular juvenile idiopathic arthritis (age two and older)
  • Enthesitis-related arthritis (age six and older)
  • Plaque psoriasis (age four and older)
  • Crohn’s disease (age six and older)
  • Hidradenitis suppurativa (age 12 and older)
  • Uveitis (age two and older)

Humira is the world’s best-selling biologic medication. It had brand sales of approximately $4.4 billion in Europe for the 12 months ending June 30, 2018, according to IQVIA.

(Source: Mylan N.V.)

Related Articles Read More >

Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE